Latest Intelligence on Diabetes and Endocrinology in Europe

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Type 2 diabetes driving epidemic

Type 2 diabetes poses one of the greatest public health threats of the 21st century. As well as increasing the potential patient population, type 2 diabetes has also raised the profile of the disease. However, a new Datamonitor report estimates that while 55 million people are affected by type 2 diabetes, only 50% of patients are diagnosed, and only 80% of those actually receive treatment.

Published By Datamonitor
21 Feb 2008
CommentWire
CommentWire

Sanofi-Aventis: slimmer pickings for Acomplia after FDA knock back

Sanofi-Aventis has received an approvable letter from the FDA for Acomplia for its weight management indication and a non-approvable letter for smoking cessation. Although it is still unclear how long a launch in weight management will be delayed, the news has already prompted a fall in the company's share price, as investors fret over the drug's prospects.

Published By Datamonitor
28 Feb 2006
ResearchWire
ResearchWire

Obesity: lack of reimbursement limits market potential

Published By Datamonitor
09 Feb 2007
CommentWire
CommentWire

Novo Nordisk: setback for inhaled insulin

Denmark-based Novo Nordisk has dropped its fast-acting mealtime inhaled insulin product AERx due to a lack of commercial potential, and will focus on long-acting inhaled formulations instead. The problems faced by Novo in marketing the drug, including low satisfaction levels and re-imbursement issues with healthcare providers will also apply to other companies developing inhaled insulin systems.

Published By Datamonitor
16 Jan 2008
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
Expert View
Expert View

GSK: orlistat becomes first OTC treatment for weight-loss in Europe

GlaxoSmithKline has received approval to sell Alli, a low dose formulation of orlistat, over-the-counter to overweight adults across the EU. The drug was previously only available by physician consultation, though it has been available over-the-counter in the US since 2007. Despite promising short term prospects, Datamonitor predicts that Alli's long term performance will be less favorable.

Published By Datamonitor
21 Apr 2009
CommentWire
CommentWire

GlaxoSmithKline: Avandia's future questioned following US report

GlaxoSmithKline is back in the hot seat following the release of a US Senate report that highlights serious health risks associated with its diabetes drug Avandia. The report also criticizes the company for its handling of safety data and although GSK has rejected these claims and issued a fierce defense of its drug, the FDA is now under pressure to order the market withdrawal of Avandia.

Published By Datamonitor
01 Mar 2010
ResearchWire
ResearchWire

Children's diet: obesity figures continue to gain weight

Published By Datamonitor
28 Jul 2005
Expert View
Expert View

Childhood obesity levels set to rise unabated

Childhood obesity is set to increase, with incidence rates growing at the fastest rates in Asia Pacific countries, particularly China, while Europe and the US will retain the highest overall ratios. Excessive consumption of energy-dense food and drinks is partly to blame, however, sedentary lifestyles, particularly a dependence on cars and public transport, are also part of the problem.

Published By Datamonitor
07 Jul 2008
Expert View
Expert View

Autoimmune therapies found wanting in type 1 diabetes

Autoimmune treatments for type 1 diabetes promise to preserve the body's own insulin production. However, three late-stage candidates - teplizumab, otelixizumab, and Diamyd - have failed to show that they can prevent beta-cell destruction in type 1 patients, confirming Datamonitor's long-held belief that there are many barriers to market entry for these treatments.

Published By Datamonitor
03 Jun 2011

« | 1 | 2 | » »|

No help is available.